Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use.
For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
Regional State Budgetary Healthcare Institution "Clinical Hospital â„–1", Smolensk, Russian Federation
SUNY Upstate Medical University, Syracuse, New York, United States
Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
Norris Cotton Cancer Center - Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Hammersmith Hospital, London, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.